Navigation Links
Neuropack MEB-9100 Series

ProductsNeuropack MEB-9100 Series
Company Nihon Kohden
Item Neuropack MEB-9100 Series
Features 
  • Stable and reliable operation with Windows 2000
  • Complete 2 or 4 channel system
  • Low noise, high CMRR, montage programmable electrode junction box
Description Neuropack is the world's first Windows 2000 notebook PC based evoked potential/EMG measuring system. It allows data sharing with other Windows based applications and is compatible with Microsoft Office 2000. Data and waveforms are easy to see on the large, sharp 14.1-inch TFT screen with 1024768 pixel resolution.
Info Nihon Kohden
Customer Service: (800) 325-0283

Related medicine products :

1. Neuropack MEB-2200 Evoked Potential/EMG Measuring System
2. Neuropack MEB-7102 Evoked Potential Measuring System
3. Neuropack Sigma MEB-5500 series Evoked Potential Measuring System
4. Neuropack M1 MEB-9200
5. Series 20000 Legacy
6. Series 24 Watt Sealed CO2 OEM Lasers
7. M/MK Series
8. EA/EKA Series
9. EHS Series
10. MLS-Series Top-Loading Autoclaves
11. Blood Coagulation Analyzer CG Series
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
Medicine Products:
(Date:8/3/2015)... ... 2015 , ... Code , an industry leader of image-based barcode reading ... Reader accessory that enables a wireless connection between the CR5000 and a ... of barcode reading applications with iPads, Galaxy Tabs, and many other products that lack ...
(Date:8/3/2015)... ... August 03, 2015 , ... Bayer has agreed to pay $56.9 million to ... a claimant alleged to have suffered an arterial blood clot including stroke and heart ... Yasmin and Ocella, has been ongoing for well-over five years. In 2009, lawsuits filed ...
(Date:8/3/2015)... , ... August 03, 2015 , ... ... agreement to Seattle-based Genelex to offer pharmacogenetic lab testing and precision medicine solutions ... health care costs. , Annually, more than 8.6 million adverse drug events ...
(Date:8/3/2015)... ... August 03, 2015 , ... Social ... , AUGUST 3, 2015 – Since winning a South by Southwest® (SXSW®) Interactive ... – an organization whose mission is to develop technology for the sake of ...
(Date:8/3/2015)... ... August 03, 2015 , ... Sensato and ... Secure Healthcare Systems” This three-day, highly interactive and immersive workshop, has been ... access to the tactics, techniques and practices required to design and develop highly ...
Breaking Medicine News(10 mins):Health News:Code Launches the T500, an Innovative Code Reader Accessory 2Health News:Code Launches the T500, an Innovative Code Reader Accessory 3Health News:Bayer Agrees To Settle Yaz Aterial Blood Clot Lawsuits 2Health News:Novation Awards Genelex First Group Purchasing Agreement for Pharmacogenetic Testing and Precision Medicine Software 2Health News:Novation Awards Genelex First Group Purchasing Agreement for Pharmacogenetic Testing and Precision Medicine Software 3Health News:Not Impossible Earns Top Awards for Technologies Benefiting Humanity 2Health News:Not Impossible Earns Top Awards for Technologies Benefiting Humanity 3Health News:Not Impossible Earns Top Awards for Technologies Benefiting Humanity 4Health News:Sensato and Divurgent are pleased to announce the development of it’s new program “Designing Secure Healthcare Systems” 2Health News:Sensato and Divurgent are pleased to announce the development of it’s new program “Designing Secure Healthcare Systems” 3Health News:Sensato and Divurgent are pleased to announce the development of it’s new program “Designing Secure Healthcare Systems” 4
... Exposure to environmental levels of the industrial chemical bisphenol A, ... long-lasting harm to testicular function, according to a new study ... The Endocrine Society,s 92nd Annual Meeting in San Diego. ... after exposure to BPA levels that are lower than what ...
... revelation that the chair of the board of Canada,s ... until April 2010 sends an unfortunate message to the ... states an editorial http://www.cmaj.ca/cgi/doi/10.1503/cmaj.100850 in CMAJ ( ... no place for the tobacco industry on the development ...
... , ... rank search results higher when there is promoter activity behind the website. , ... (PRWEB) June 21, 2010 -- The Active ... called Active Search Results Page Ranking Technology (ASR Ranking). , , ,ASR Ranking allows ...
... fish that used to be feminized after chemicals, such as ... Treatment Plant and into Boulder Creek, are taking longer to ... process, according to a new study. The results will be ... San Diego. Although the levels of the chemicals that ...
... ... performance for the year ending March 31, 2010 in spite of the economic turmoil’s impact ... the second half of 2010 compared with the same period last year. , ... Auckland, New Zealand (Vocus) June 21, 2010 ...
... The ... 33 times greater than that reported for our accredited ambulatory surgery centers. , ... (PRWEB) June 18, 2010 ... Michael Jhung et al (JAMA 2010;303(22):2273 - 2279) correctly places emphasis on the importance ...
Cached Medicine News:Health News:Early-life exposure to BPA may affect testis function in adulthood 2Health News:CMAJ calls for resignation of IDRC chair Barbara McDougall 2Health News:Active Search Results Announces its New Search Engine Ranking Algorithm 2Health News:Active Search Results Announces its New Search Engine Ranking Algorithm 3Health News:Chemicals remaining after wastewater treatment change the gender of fish 2Health News:Health IT Adoption Rates Drive Orion Health Continued Global Growth 2Health News:Health IT Adoption Rates Drive Orion Health Continued Global Growth 3Health News:Health IT Adoption Rates Drive Orion Health Continued Global Growth 4Health News:Health IT Adoption Rates Drive Orion Health Continued Global Growth 5Health News:Infection Rate in Accredited Ambulatory Facilities is Lower than in Hospitals 2
(Date:8/3/2015)... Immune Pharmaceuticals, Inc. ("Immune") (NASDAQ: IMNP ... , will present live at VirtualInvestorConferences.com on August 6, ... 11:30AM EDT LINK:    http://tinyurl.com/aug6-pre-imnp ... investors are invited to ask the company questions in ... as the association,s "virtual trade booth." If attendees are ...
(Date:8/3/2015)... 2015  EnteroMedics Inc. (NASDAQ: ETRM ), the developer ... metabolic diseases and other gastrointestinal disorders, today announced that ... the Board of Directors, effective July 31, 2015.  Ms. ... the 2018 annual meeting or until her successor is ... in an executive capacity in the healthcare industry for ...
(Date:8/2/2015)...  Isis Pharmaceuticals, Inc. (NASDAQ: ISIS ) ... discover and develop antisense therapies for cardiovascular, metabolic ... a broad existing relationship between the two companies ... areas using novel RNA-targeted treatments. It also enables ... technology to diseases of the kidney. ...
Breaking Medicine Technology:Immune Pharmaceuticals to Webcast Live at VirtualInvestorConferences.com August 6 2EnteroMedics Announces Appointment of Lori C. McDougal to the Board of Directors 2EnteroMedics Announces Appointment of Lori C. McDougal to the Board of Directors 3AstraZeneca and Isis Pharmaceuticals to Discover and Develop Antisense Drugs for Cardiovascular, Metabolic and Renal Diseases 2AstraZeneca and Isis Pharmaceuticals to Discover and Develop Antisense Drugs for Cardiovascular, Metabolic and Renal Diseases 3AstraZeneca and Isis Pharmaceuticals to Discover and Develop Antisense Drugs for Cardiovascular, Metabolic and Renal Diseases 4